Multi-centre, Open-label Extension trial of treatment with ZD1839 (Iressa) in patients who have been treated in other ZD1839 Clinical Trials and may benefit from continued Monotherapy ZD 1839.
18 Years +
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals
No locations available